XM Therapeutics

📍 Providence, United States🗓 Founded 2022👥 4 employees💰 Last funded Nov 2024
Biotechnology Research🌐 xmtherapeutics.com
Website LinkedIn
The Extracellular Matrix (ECM) - the scaffolding material that organizes cells into tissues and organs - is a proactive participant in chronic disorders enabling continued inflammation, fibrosis and ischemia. Spun off from Brown University in 2022, XM Therapeutics is developing a platform technology to directly modulate the dysfunctional ECM to improve tissue function and enable organ repair. We generate injectable, acellular designer ECM Particles sourced from human 3D cell cultures. Our initial focus is on cardiovascular and pulmonary indications with significant additional potential in other diseases. We are a Providence, RI - based seed stage start-up with a clear mission: to improve the health status of patients with chronic disorders by modulating and repairing the dysfunctional Extracellular Matrix.
1
Total investors
1
Early stage
0
Mid stage
0
Late stage
2022
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in XM Therapeutics?
XM Therapeutics has 1 investors on record on gritt.io, including 1 early-stage backers.
When did XM Therapeutics last raise funding?
The most recent investment in XM Therapeutics recorded on gritt.io was in November 2024.
When was XM Therapeutics founded?
XM Therapeutics was founded in 2022.
What industry is XM Therapeutics in?
XM Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is XM Therapeutics based?
XM Therapeutics is headquartered in Providence, United States.